Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs SoFi Technologies Inc (SOFI) Price & Performance

IDEXX Laboratories, Inc.Trade
SoFi Technologies IncTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs SoFi Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $519.96 (market cap $40.43B), while SoFi Technologies Inc trades at $15.77 (market cap $20.16B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2× SoFi Technologies Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 49,646,331). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and SoFi Technologies Inc for 60 Days on average.

IDXXSOFI
Market Cap
$40.43B$20.16B
Volume
692,16449,646,331
Sector
HealthFinancials
52-Week High
$766.68$32.21
52-Week Low
$504.70$15.15
Typical Hold Time
46 Days60 Days
Enterprise Value
$41.32B$20.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.

The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.

SoFi Technologies Inc

SoFi Technologies (SOFI) trades at $15.72, up 0.38% on the day, but remains near 52-week lows amid a bearish technical outlook. The company reported strong revenue growth, with 2025 revenue reaching $3.61 billion and net income of $481.32 million, though cash flow from operations remains negative. Analyst consensus is mixed with a $21.58 price target, but technical indicators signal caution.

SoFi's growth trajectory and improving profitability present long-term potential, but near-term risks include persistent negative operating cash flow, high valuation multiples, and sensitivity to interest rates. Execution on loan originations and stablecoin initiatives will be critical for stock performance.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IDXX

No sentiment data available yet.

SOFI
69% Buy31% Sell
Avg holding period · 60 Days

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →

About SoFi Technologies Inc

SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.

Read more on SOFI →